Translating Glutamate: From Pathophysiology to Treatment

Common polygenic variation contributes to risk of schizophrenia and bipolar disorder

The International Schizophrenia Consortium (2009) · Nature · doi:10.1038/nature08185 · Cited by 4,821

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879

Antidepressant effects of ketamine in depressed patients

Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.

Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766

Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans: Psychotomimetic, Perceptual, Cognitive, and Neuroendocrine Responses

Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330

Recent advances in the phencyclidine model of schizophrenia

(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904

mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists

Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881

The Neural Basis of Addiction: A Pathology of Motivation and Choice

Kalivas, P. W., & Volkow, N. D. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1403 · Cited by 2,757

Drug Addiction and Its Underlying Neurobiological Basis: Neuroimaging Evidence for the Involvement of the Frontal Cortex

Goldstein, R. Z., & Volkow, N. D. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.10.1642 · Cited by 2,667

Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence

Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020

Rare Structural Variants Disrupt Multiple Genes in Neurodevelopmental Pathways in Schizophrenia

Walsh, T., McClellan, J. M., McCarthy, S. E., Addington, A. M., Pierce, S. B., Cooper, G. M., Nord, A. S., Kusenda, M., Malhotra, D., Bhandari, A., et al. (2008) · Science · doi:10.1126/science.1155174 · Cited by 1,800

The glutamate homeostasis hypothesis of addiction

Kalivas, P. W. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2515 · Cited by 1,350

Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors

Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103

Relationship Between Dopamine D 2 Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode Schizophrenia

Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090

Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database

Allen, N. C., Bagade, S., McQueen, M. B., Ioannidis, J. P. A., Kavvoura, F. K., Khoury, M. J., Tanzi, R. E., & Bertram, L. (2008) · Nature Genetics · doi:10.1038/ng.171 · Cited by 1,054

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040

Reversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats

Moghaddam, B., & Adams, B. W. (1998) · Science · doi:10.1126/science.281.5381.1349 · Cited by 1,006

A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression

Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963

Etiological heterogeneity in autism spectrum disorders: More than 100 genetic and genomic disorders and still counting

Betancur, C. (2011) · Brain Research · doi:10.1016/j.brainres.2010.11.078 · Cited by 954

Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders

Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2462 · Cited by 894

Regulation of Neurotransmitter Release by Metabotropic Glutamate Receptors

Cartmell, J., & Schoepp, D. D. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0750889.x · Cited by 883

Metabotropic glutamate receptors: electrophysiological properties and role in plasticity

Anwyl, R. (1999) · Brain Research Reviews · doi:10.1016/s0165-0173(98)00050-2 · Cited by 799

Functional antagonists at the NMDA receptor complex exhibit antidepressant actions

Trullas, R., & Skolnick, P. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90204-j · Cited by 785

Mismatch negativity in schizophrenia: a meta-analysis

Umbricht, D., & Krljes, S. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2004.12.002 · Cited by 742

Drug Seeking Becomes Compulsive After Prolonged Cocaine Self-Administration

Vanderschuren, L. J. M. J., & Everitt, B. J. (2004) · Science · doi:10.1126/science.1098975 · Cited by 733

Metabotropic glutamate receptors: Synaptic transmission, modulation, and plasticity

Nakanishi, S. (1994) · Neuron · doi:10.1016/0896-6273(94)90043-4 · Cited by 716

Unveiling the Functions of Presynaptic Metabotropic Glutamate Receptors in the Central Nervous System

Schoepp, D. D. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29296-x · Cited by 693

Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression

aan het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., & Mathew, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.038 · Cited by 690

Role of cortical N-methyl-D-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia.

Javitt, D. C., Steinschneider, M., Schroeder, C. E., & Arezzo, J. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11962 · Cited by 662

Functional connectivity density mapping

Tomasi, D. G., & Volkow, N. D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001414107 · Cited by 645

Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056

Jacquemont, S., Curie, A., des Portes, V., Torrioli, M. G., Berry-Kravis, E., Hagerman, R. J., Ramos, F. J., Cornish, K., He, Y., Paulding, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001708 · Cited by 609

Metabotropic glutamate receptors as novel targets for anxiety and stress disorders

Swanson, C. J., Bures, M., Johnson, M. P., Linden, A.-M., Monn, J. A., & Schoepp, D. D. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1630 · Cited by 607

Effects of Intravenous Ketamine on Explicit and Implicit Measures of Suicidality in Treatment-Resistant Depression

Price, R. B., Nock, M. K., Charney, D. S., & Mathew, S. J. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.04.029 · Cited by 600

The Autistic Neuron: Troubled Translation?

Kelleher, R. J., & Bear, M. F. (2008) · Cell · doi:10.1016/j.cell.2008.10.017 · Cited by 598

Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly

Sheline, Y. I., Raichle, M. E., Snyder, A. Z., Morris, J. C., Head, D., Wang, S., & Mintun, M. A. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.024 · Cited by 597

GABA Neurons and the Mechanisms of Network Oscillations: Implications for Understanding Cortical Dysfunction in Schizophrenia

González‐Burgos, G., & Lewis, D. A. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn070 · Cited by 592

Ketamine-Induced Deficits in Auditory and Visual Context-Dependent Processing in Healthy Volunteers

Umbricht, D., Schmid, L., Koller, R., Vollenweider, F. X., Hell, D., & Javitt, D. C. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.12.1139 · Cited by 587

The Mismatch Negativity

Näätänen, R. (1995) · Ear and Hearing · doi:10.1097/00003446-199502000-00002 · Cited by 582

Glutamate and Schizophrenia: Phencyclidine, N‐Methyl‐d‐Aspartate Receptors, and Dopamine–Glutamate Interactions

Javitt, D. C. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(06)78003-5 · Cited by 568

The Glutamatergic Dysfunction Hypothesis for Schizophrenia

Coyle, J. T. (1996) · Harvard Review of Psychiatry · doi:10.3109/10673229609017192 · Cited by 568

Autism spectrum disorders-a genetics review

Miles, J. H. (2011) · Genetics in Medicine · doi:10.1097/gim.0b013e3181ff67ba · Cited by 567

Glutamate as a therapeutic target in psychiatric disorders

Javitt, D. C. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001551 · Cited by 534

Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients

Nordström, A., Farde, L., Wiesel, F., Forslund, K., Pauli, S., Halldin, C., & Uppfeldt, G. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90288-o · Cited by 527

An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder

Preskorn, S., Baker, B., Kolluri, S., Menniti, F. S., Krams, M., & Landen, J. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818a6cea · Cited by 524

Excitatory Amino Acid Neurotransmission: NMDA Receptors and Hebb-Type Synaptic Plasticity

Cotman, C. W., & Monaghan, D. T. (1988) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.11.030188.000425 · Cited by 484

Amplitude of low-frequency oscillations in schizophrenia: A resting state fMRI study

Hoptman, M. J., Zuo, X., Butler, P. D., Javitt, D. C., D’Angelo, D., Mauro, C. J., & Milham, M. P. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.09.030 · Cited by 470

Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus

Garcia, L. S. B., Comim, C. M., Valvassori, S. S., Réus, G. Z., Barbosa, L. M., Andreazza, A. C., Stertz, L., Fries, G. R., Gavioli, E. C., Kapczinski, F., et al. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.07.027 · Cited by 454

Modulation of N -methyl- d -aspartate receptor function by glycine transport

Bergeron, R., Meyer, T. M., Coyle, J. T., & Greene, R. W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15730 · Cited by 418

N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: The final common pathway on the road to schizophrenia?

Kantrowitz, J. T., & Javitt, D. C. (2010) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2010.04.006 · Cited by 414

Mismatch Negativity Deficits Are Associated With Poor Functioning in Schizophrenia Patients

Light, G. A., & Braff, D. L. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.2.127 · Cited by 407

N-Acetylcysteine reverses cocaine-induced metaplasticity

Moussawi, K., Pacchioni, A. M., Moran, M., Olive, M. F., Gass, J. T., Lavín, A., & Kalivas, P. W. (2009) · Nature Neuroscience · doi:10.1038/nn.2250 · Cited by 403

Ceftriaxone Restores Glutamate Homeostasis and Prevents Relapse to Cocaine Seeking

Knackstedt, L. A., Meléndez, R. I., & Kalivas, P. W. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.07.018 · Cited by 396

Glutamate-based antidepressants: 20 years on

Skolnick, P., Popik, P., & Trullás, R. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.09.002 · Cited by 386

Redox dysregulation, neurodevelopment, and schizophrenia

Do, K. Q., Cabungcal, J. H., Frank, A., Steullet, P., & Cuenod, M. (2009) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2009.05.001 · Cited by 384

Transition to Addiction Is Associated with a Persistent Impairment in Synaptic Plasticity

Kasanetz, F., Deroche‐Gamonet, V., Berson, N., Balado, É., Lafourcade, M., Manzoni, O. J., & Piazza, P. V. (2010) · Science · doi:10.1126/science.1187801 · Cited by 382

Children and adolescents with autism exhibit reduced MEG steady-state gamma responses

Wilson, T. W., Rojas, D. C., Reite, M. L., Teale, P. D., & Rogers, S. J. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.07.002 · Cited by 350

Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior

Basu, A. C., Tsai, G. E., Ma, C.-L., Ehmsen, J. T., Mustafa, A. K., Han, L., Jiang, Z. I., Benneyworth, M. A., Froimowitz, M., LANGE, N. D., et al. (2008) · Molecular Psychiatry · doi:10.1038/mp.2008.130 · Cited by 340

Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia.

Linderholm, K., Skogh, E., Olsson, S., Dahl, M., Holtze, M., Engberg, G., Samuelsson, M., & Erhardt, S. (2012) · Schizophrenia bulletin · doi:10.1093/schbul/sbq086 · Cited by 335

A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia

Bendikov, I., Nadri, C., Amar, S., Panizzutti, R., DEMIRANDA, J., Wolosker, H., & Agam, G. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.10.010 · Cited by 323

Resting Brain Connectivity: Changes during the Progress of Alzheimer Disease

Zhang, H.-Y., Wang, S.-J., Liu, B., Ma, Z.-L., Yang, M., Zhang, Z.-J., & Teng, G.-J. (2010) · Radiology · doi:10.1148/radiol.10091701 · Cited by 320

Validating γ oscillations and delayed auditory responses as translational biomarkers of autism

Gandal, M. J., Edgar, J. C., Ehrlichman, R. S., Mehta, M., Roberts, T. P. L., & Siegel, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.09.031 · Cited by 314

Reduced Dendritic Spine Density in Auditory Cortex of Subjects with Schizophrenia

Sweet, R. A., Henteleff, R. A., Zhang, W., Sampson, A. R., & Lewis, D. A. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.67 · Cited by 290

Increased Anterior Cingulate Cortical Activity in Response to Fearful Faces: A Neurophysiological Biomarker that Predicts Rapid Antidepressant Response to Ketamine

Salvadore, G., Cornwell, B. R., Colon-Rosario, V., Coppola, R., Grillon, C., Zarate, C. A., & Manji, H. K. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.08.014 · Cited by 277

Glutamatergic and resting state functional connectivity correlates of severity in major depression - the role of pregenual anterior cingulate cortex and anterior insula

Horn (2010) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2010.00033 · Cited by 276

Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects

Krystal, J. H., Abi-Saab, W., Perry, E., D’Souza, D. C., Liu, N., Gueorguieva, R., McDougall, L., Hunsberger, T., Belger, A., Levine, L., et al. (2005) · Psychopharmacology · doi:10.1007/s00213-004-1982-8 · Cited by 272

The Metabotropic Glutamate 2/3 Receptor Agonists LY354740 and LY379268 Selectively Attenuate Phencyclidine versus d-Amphetamine Motor Behaviors in Rats

Cartmell, J., Monn, J. A., & Schoepp, D. D. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35084-0 · Cited by 270

Strategies to Enhance N-Methyl-D-Aspartate Receptor-Mediated Neurotransmission in Schizophrenia, a Critical Review and Meta-Analysis

Tsai, G. E., & Lin, P. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210790361452 · Cited by 269

MODEL PSYCHOSES AND SCHIZOPHRENIA

Luby, E. D., Gottlieb, J. S., Cohen, B. D., Rosenbaum, G., & Domino, E. F. (1962) · American Journal of Psychiatry · doi:10.1176/ajp.119.1.61 · Cited by 268

Reduced d-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients

Hashimoto, K., Engberg, G., Shimizu, E., Nordin, C., Lindström, L. H., & Iyo, M. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.04.023 · Cited by 267

Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging

Howes, O. D., Egerton, A., Allan, V., McGuire, P., Stokes, P. R. A., & Kapur, S. (2009) · Current pharmaceutical design · doi:10.2174/138161209788957528 · Cited by 261

The Role of Cystine-Glutamate Exchange in Nicotine Dependence in Rats and Humans

Knackstedt, L. A., LaRowe, S., Mardikian, P., Malcolm, R., Upadhyaya, H., Hedden, S., Markou, A., & Kalivas, P. W. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.10.040 · Cited by 260

Toward Fulfilling the Promise of Molecular Medicine in Fragile X Syndrome

Krueger, D. D., & Bear, M. F. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-061109-134644 · Cited by 259

NMDA receptors and schizophrenia

Kristiansen, L. V., Huerta, I., BENEYTO, M., & Meador‐Woodruff, J. H. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.08.013 · Cited by 248

How specific are deficits in mismatch negativity generation to schizophrenia?

Umbricht, D., Koller, R., Schmid, L., Skrabo, A., Grübel, C., Huber, T., & Stassen, H. H. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01642-6 · Cited by 247

Reduced Interhemispheric Resting State Functional Connectivity in Cocaine Addiction

Kelly, C. A. M., Zuo, X., Gotimer, K., Cox, C. L., Lynch, L. K., Brock, D. C., Imperati, D., Garavan, H., Rotrosen, J., Castellanos, F. X., et al. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.11.022 · Cited by 235

White matter integrity and prediction of social and role functioning in subjects at ultra-high risk for psychosis

Karlsgodt, K. H., Niendam, T. A., Bearden, C. E., & Cannon, T. D. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.03.013 · Cited by 229

Neuropsychiatric applications of DTI – a review

Lim, K. O., & Helpern, J. A. (2002) · NMR in Biomedicine · doi:10.1002/nbm.789 · Cited by 228

N-Acetylcysteine Reduces Extinction Responding and Induces Enduring Reductions in Cue- and Heroin-Induced Drug-Seeking

Zhou, W., & Kalivas, P. W. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.06.008 · Cited by 225

Anterior Cingulate Desynchronization and Functional Connectivity with the Amygdala During a Working Memory Task Predict Rapid Antidepressant Response to Ketamine

Salvadore, G., Cornwell, B. R., Sambataro, F., Latov, D. R., Colon-Rosario, V., Carver, F. W., Holroyd, T., Diazgranados, N., Machado‐Vieira, R., Grillon, C., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.24 · Cited by 220

LY354740, an mGlu2/3 Receptor Agonist as a Novel Approach to Treat Anxiety/Stress

Schoepp, D. D., Wright, R. A., Levine, L. R., Gaydos, B. L., & Potter, W. Z. (2003) · Stress · doi:10.1080/1025389031000146773 · Cited by 207

Cocaine self-administration selectively abolishes LTD in the core of the nucleus accumbens

Martín, M., Chen, B. T., Hopf, F. W., Bowers, M. S., & Bonci, A. (2006) · Nature Neuroscience · doi:10.1038/nn1713 · Cited by 205

Upregulation of Glt1 Attenuates Cue-Induced Reinstatement of Cocaine-Seeking Behavior in Rats

Sari, Y., Smith, K. D., Ali, P. K., & Rebec, G. V. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1746-09.2009 · Cited by 200

Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model

Labrie, V., Fukumura, R., Rastogi, A., Fick, L. J., Wang, W., Boutros, P. C., Kennedy, J. L., Semeralul, M. O., Lee, F. H., Baker, G. B., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp261 · Cited by 193

Increased brain d-amino acid oxidase (DAAO) activity in schizophrenia

Madeira, C., Freitas, M. E., Vargas-Lopes, C., Wolosker, H., & Panizzutti, R. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.02.002 · Cited by 191

Auditory event-related potential abnormalities in bipolar disorder and schizophrenia

O'Donnell, B. F., Vohs, J. L., Hetrick, W. P., Carroll, C. A., & Shekhar, A. (2004) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2004.02.001 · Cited by 190

Cortical Kynurenine Pathway Metabolism: A Novel Target for Cognitive Enhancement in Schizophrenia

Wonodi, I., & Schwarcz, R. M. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq002 · Cited by 190

Family History of Alcohol Dependence and Initial Antidepressant Response to an N-methyl-D-aspartate Antagonist

Phelps, L. E., Brutsché, N. E., Moral, J. R., Luckenbaugh, D. A., Manji, H. K., & Zarate, C. A. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.09.029 · Cited by 188

Efficacy and Tolerability of an mGlu2/3 Agonist in the Treatment of Generalized Anxiety Disorder

Dunayevich, E., Erickson, J., Levine, L. R., Landbloom, R. P., Schoepp, D. D., & Tollefson, G. D. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301531 · Cited by 181

Glutamate Receptors in Extinction and Extinction-Based Therapies for Psychiatric Illness

Myers, K. M., Carlezon, W. A., & Davis, M. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.88 · Cited by 177

Fragile X: Leading the Way for Targeted Treatments in Autism

Wang, L. W., Berry-Kravis, E., & Hagerman, R. J. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2010.05.005 · Cited by 176

The neurobiology of D-amino acid oxidase and its involvement in schizophrenia

Verrall, L., Burnet, P. W. J., Betts, J. F., & Harrison, P. J. (2009) · Molecular Psychiatry · doi:10.1038/mp.2009.99 · Cited by 173

In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats

Battaglia, G., Monn, J. A., & Schoepp, D. D. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00442-4 · Cited by 163

Intracortical Mechanisms of Mismatch Negativity Dysfunction in Schizophrenia

Javitt, D. C. (2000) · Audiology and Neurotology · doi:10.1159/000013882 · Cited by 161

Ketamine Produces Lasting Disruptions in Encoding of Sensory Stimuli

Maxwell, C. R., Ehrlichman, R. S., Liang, Y., Trief, D., Kanes, S., Karp, J. D., & Siegel, S. J. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.091199 · Cited by 160

Mismatch negativity in children with autism and typical development

Dunn, M. A., Gomes, H., & Gravel, J. (2008) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-007-0359-3 · Cited by 159

Mismatch Negativity in Aging and in Alzheimer’s and Parkinson’s Diseases

Pekkonen, E. (2000) · Audiology and Neurotology · doi:10.1159/000013883 · Cited by 157

Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s)

Johnson, M. P., Barda, D., Britton, T. C., Emkey, R., Hornback, W. J., Jagdmann, G. E., McKinzie, D. L., Nisenbaum, E. S., Tizzano, J. P., & Schoepp, D. D. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2099-9 · Cited by 156

Deviance-elicited Changes in Event-related Potentials are Attenuated by Ketamine in Mice

Ehrlichman, R. S., Maxwell, C. R., Majumdar, S., & Siegel, S. J. (2008) · Journal of Cognitive Neuroscience · doi:10.1162/jocn.2008.20097 · Cited by 154

1H-MRS at 4 Tesla in minimally treated early schizophrenia

Bustillo, J. R., Rowland, L. M., Mullins, P., Jung, R., Chen, H., Qualls, C., Hammond, R., Brooks, W. M., & Lauriello, J. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.121 · Cited by 153

Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis

Heekeren, K., Daumann, J., Neukirch, A., Stock, C., Kawohl, W., Norra, C., Waberski, T. D., & Gouzoulis‐Mayfrank, E. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1129-4 · Cited by 152

Candidate Electrophysiological Endophenotypes of Hyper-Reactivity to Change in Autism

Gomot, M., Blanc, R., Cléry, H., Roux, S., Barthélémy, C., & Bruneau, N. (2010) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-010-1091-y · Cited by 151

The Effects of a Sub-Anaesthetic Dose of Ketamine on Human Selective Attention

Oranje, B. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00118-9 · Cited by 147

Effect of ketamine on the neuromagnetic mismatch field in healthy humans

Kreitschmann‐Andermahr, I., Rosburg, T., Demme, U., Gaser, E., Nowak, H., & Sauer, H. (2001) · Cognitive Brain Research · doi:10.1016/s0926-6410(01)00043-x · Cited by 144

Molecular Genetics of Addiction and Related Heritable Phenotypes

Uhl, G. R., Drgon, T., Johnson, C., Li, C., Contoreggi, C. S., Hess, J., Naiman, D. Q., & Liu, Q. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1441.018 · Cited by 141

The Emerging Link Between Autoimmune Disorders and Neuropsychiatric Disease

Kayser, M. S., & Dalmau, J. (2011) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.23.1.90 · Cited by 133

Effects of an NMDA-receptor antagonist MK-801 on an MMN-like response recorded in anesthetized rats

Tikhonravov, D. L., Neuvonen, T., Pertovaara, A., Savioja, K., Ruusuvirta, T., Näätänen, R., & Carlson, S. (2008) · Brain Research · doi:10.1016/j.brainres.2008.02.006 · Cited by 131

Co-Administration of a D-Amino Acid Oxidase Inhibitor Potentiates the Efficacy of D-Serine in Attenuating Prepulse Inhibition Deficits After Administration of Dizocilpine

Hashimoto, K., Fujita, Y., Horio, M., Kunitachi, S., Iyo, M., Ferraris, D. V., & Tsukamoto, T. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.01.002 · Cited by 128

Diffusion based abnormality markers of pathology: Toward learned diagnostic prediction of ASD

Ingalhalikar, M., Parker, D., Bloy, L., Roberts, T. P. L., & Verma, R. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.05.023 · Cited by 121

Targeting Glutamatergic Signaling for the Development of Novel Therapeutics for Mood Disorders

Machado‐Vieira, R., Salvadore, G., Ibrahim, L. A., Diazgranados, N., & Zarate, C. A. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788168010 · Cited by 118

Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice

Linden, A.-M., Shannon, H. E., Baez, M., Yu, J., Koester, A., & Schoepp, D. D. (2004) · Psychopharmacology · doi:10.1007/s00213-004-2098-x · Cited by 117

Serine racemase deletion disrupts memory for order and alters cortical dendritic morphology

DeVito, L. M., Balu, D. T., Kanter, B. R., Lykken, C., Basu, A. C., COYLE, J. T., & Eichenbaum, H. (2010) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2010.00656.x · Cited by 114

Deviance-related electrophysiological activity in mice: is there mismatch negativity in mice?

Umbricht, D., Vyssotki, D., Латанов, А. В., Nitsch, R. M., & Lipp, H. (2004) · Clinical Neurophysiology · doi:10.1016/j.clinph.2004.08.015 · Cited by 112

Acute effects of ketamine in the holeboard, the elevated-plus maze, and the social interaction test in Wistar rats

Silvestre, J. S., Nadal, R. A., S, M. A. P., & Ferr�, N. (1997) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1997)5:1 · Cited by 110

Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patients

Hashimoto, K., Engberg, G., Shimizu, E., Nordin, C., Lindström, L., & Iyo, M. (2005) · BMC Psychiatry · doi:10.1186/1471-244x-5-6 · Cited by 106

Modulators of the Glutamatergic System: Implications for the Development of Improved Therapeutics in Mood Disorders

Zarate, C. A., Quiroz, J. A., Quiroz, J. A., Manji, H. K., Payne, J. L., Kornstein, S. G., Manji, A. H. K., & MD (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4204 · Cited by 105

Glycine Therapy of Schizophrenia

Waziri, R. (1988) · Biological Psychiatry · doi:10.1016/0006-3223(88)90093-5 · Cited by 100

Preclinical Pharmacology of mGlu2 / 3 Receptor Agonists: Novel Agents for Schizophrenia?

Schoepp, D. D., & Marek, G. J. (2002) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007024606177 · Cited by 100

Glycine Transport Inhibitors and the Treatment of Schizophrenia

Javitt, D. C. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.09.017 · Cited by 100

Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors

Javitt, D. C., Balla, A., Sershen, H. W., & Lajtha, Á. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00237-6 · Cited by 99

Dizocilpine antagonizes the effect of chronic imipramine on learned helplessness in rats

Meloni, D., Gambarana, C., Montis, M. G. D., Pra, P. D., Taddei, I., & Tagliamonte, A. (1993) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(93)90374-3 · Cited by 96

Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification.

Javitt, D. C. (2009) · PubMed · Cited by 94

Antagonism of phencyclidine-induced hyperactivity by glycine in mice

Tóth, E., & Lajtha, Á. (1986) · Neurochemical Research · doi:10.1007/bf00965013 · Cited by 94

Schizophrenia: Moving Beyond Monoamine Antagonists

Conn, P. J., Tamminga, C. A., Schoepp, D. D., & Lindsley, C. W. (2008) · Molecular Interventions · doi:10.1124/mi.8.2.7 · Cited by 84

Effects of the NMDA receptor antagonist ketamine on flavor memory: Conditioned aversion, latent inhibition, and habituation of neophobia

Aguado, L., Antonio, A. S., Pérez, L., del Valle, R., & Gómez, J. (1994) · Behavioral and Neural Biology · doi:10.1016/s0163-1047(05)80010-x · Cited by 82

Schizophrenia-like deficits in auditory P1 and N1 refractoriness induced by the psychomimetic agent phencyclidine (PCP)

Javitt, D. C., Jayachandra, M., Lindsley, R. W., Specht, C. M., & Schroeder, C. E. (2000) · Clinical Neurophysiology · doi:10.1016/s1388-2457(99)00313-2 · Cited by 79

Chronic treatment with 1-aminocyclopropanecarboxylic acid desensitizes behavioral responses to compounds acting at the N-methyl-d-aspartate receptor complex

Skolnick, P., Miller, R. L., Young, A. J., Boje, K. M. K., & Trullás, R. (1992) · Psychopharmacology · doi:10.1007/bf02245261 · Cited by 78

Antidepressant-like effects of NMDA-receptor antagonist injected into the dorsal hippocampus of rats

Padovan, C. M., & Guimarães, F. S. (2003) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2003.09.015 · Cited by 78

Accuracy and stability of measuring GABA, glutamate, and glutamine by proton magnetic resonance spectroscopy: A phantom study at 4 Tesla

Henry, M., Lauriat, T. L., Shanahan, M. E., Renshaw, P. F., & Jensen, J. E. (2010) · Journal of Magnetic Resonance · doi:10.1016/j.jmr.2010.11.003 · Cited by 73

Therapeutic Implications of the Hyperglutamatergic Effects of NMDA Antagonists

Krystal, J. H. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00102-5 · Cited by 71

Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: implications for schizophrenia and substance abuse

Javitt, D. C., & Frusciante, M. J. (1997) · Psychopharmacology · doi:10.1007/s002130050168 · Cited by 70

Brief Report: Acamprosate in Fragile X Syndrome

Erickson, C. A., Mullett, J. E., & McDougle, C. J. (2010) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-010-0988-9 · Cited by 67

Imaging the Glutamate System in Humans: Relevance to Drug Discovery for Schizophrenia

Stone, J. M. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788957438 · Cited by 66

Midlatency auditory event-related potentials in mice: comparison to midlatency auditory ERPs in humans

Umbricht, D., Vyssotki, D., Латанов, А. В., Nitsch, R. M., Brambilla, R., D’Adamo, P., & Lipp, H.-P. (2004) · Brain Research · doi:10.1016/j.brainres.2004.05.097 · Cited by 62

Genetic loss of D‐amino acid oxidase activity reverses schizophrenia‐like phenotypes in mice

Labrie, V., Wang, W., Barger, S. W., Baker, G. B., & Roder, J. (2009) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2009.00529.x · Cited by 56

Functional connectivity in blood oxygenation level‐dependent and cerebral blood volume‐weighted resting state functional magnetic resonance imaging in the rat brain

Magnuson, M. E., Majeed, W., & Keilholz, S. D. (2010) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.22295 · Cited by 53

New evidence for the antidepressant activity of MK-801, a non-competitive antagonist of NMDA receptors.

Papp, M., & Moryl, E. (1994) · PubMed · Cited by 51

Evaluation of a bolus/infusion protocol for 11C-ABP688, a PET tracer for mGluR5

Burger, C., Deschwanden, A., Ametamey, S. M., Johayem, A., Mancosu, B., Wyss, M. T., Hasler, G., & Buck, A. (2010) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2010.04.107 · Cited by 45

Dopamine and 5-HT turnover are increased by the mGlu2/3 receptor agonist LY379268 in rat medial prefrontal cortex, nucleus accumbens and striatum

Cartmell, J., Salhoff, C. R., Perry, K. W., Monn, J. A., & Schoepp, D. D. (2000) · Brain Research · doi:10.1016/s0006-8993(00)03067-5 · Cited by 44

Ketamine blocks a conditioned taste aversion (CTA) in neonatal rats1

Mickley, G. A., Schaldach, M. A., Snyder, K. J., Balogh, S. A., Len, T., Neimanis, K., Goulis, P., Hug, J., Sauchak, K., Remmers-Roeber, D. R., et al. (1998) · Physiology & Behavior · doi:10.1016/s0031-9384(98)00097-3 · Cited by 44

Effect of peripheral NMDA receptor blockade with ketamine on chronic myofascial pain in temporomandibular disorder patients: a randomized, double-blinded, placebo-controlled trial.

Castrillón, E., Cairns, B. E., Ernberg, M. M., Wang, K., Sessle, B. J., Arendt‐Nielsen, L., & Svensson, P. (2008) · PubMed · Cited by 41

Drug-Induced Plasticity Contributing to Heightened Relapse Susceptibility: Neurochemical Changes and Augmented Reinstatement in High-Intake Rats

Madayag, A., Kau, K. S., Lobner, D., Mantsch, J. R., Wisniewski, S., & Baker, D. L. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.1342-09.2010 · Cited by 37

A Role for Noradrenergic Transmission in the Actions of Phencyclidine and the Antipsychotic and Antistress Effects of mGlu2/3 Receptor Agonists

Swanson, C. J., & Schoepp, D. D. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.019 · Cited by 37

Identification and evaluation of [11C]GSK931145 as a novel ligand for imaging the type 1 glycine transporter with positron emission tomography

Passchier, J., Gentile, G., Porter, R. A., Herdon, H. J., Salinas, C. A., Jakobsen, S., Audrain, H., Laruelle, M. A., & Gunn, R. N. (2010) · Synapse · doi:10.1002/syn.20760 · Cited by 32

Metabotropic glutamate receptor targets for neuropsychiatric disorders

Linden, A.-M., & Schoepp, D. D. (2006) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2006.10.018 · Cited by 31

Central N-acetyl aspartylglutamate deficit: a possible pathogenesis of schizophrenia.

Tsai, S. (2005) · PubMed · Cited by 31

Brain Serotonin Transporter Occupancy by Oral Sibutramine Dosed to Steady State: A PET Study Using 11C-DASB in Healthy Humans

Talbot, P. S., Bradley, S., Clarke, C. P., Babalola, K., Philipp, A., Brown, G. D., McMahon, A. W., & Matthews, J. C. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.182 · Cited by 28

PET and SPET Molecular Imaging: Focus on Serotonin System

Moresco, R. M., Matarrese, M., & Fazio, F. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606778522140 · Cited by 21

Sensitization of rat facial cutaneous mechanoreceptors by activation of peripheral N-methyl-d-aspartate receptors

Gazerani, P., Dong, X., Wang, M., Kumar, U., & Cairns, B. E. (2010) · Brain Research · doi:10.1016/j.brainres.2010.01.018 · Cited by 20

5-Hydroxytryptamine2A (5-HT2A) receptor regulation in rat prefrontal cortex: Interaction of a phenethylamine hallucinogen and the metabotropic glutamate2/3 receptor agonist LY354740

Marek, G. J., Wright, R. A., & Schoepp, D. D. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.05.021 · Cited by 19

Murine diffusion imaging using snapshot interleaved EPI acquisition at 7 T

Guilfoyle, D. N., Gerum, S. V., & Hrabě, J. (2011) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2011.04.011 · Cited by 9

Deficits in Auditory and Visual Context-Dependent Processing in Schizophrenia

Javitt, D. C., Shelley, A.-M., Silipo, G., & Lieberman, J. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.12.1131 · Cited by 4

P.3.e.009 Glycine reuptake inhibitor RG1678: results of the proof-of-concept study for the treatment of negative symptoms in schizophrenia

Umbricht, D., Martin-Facklam, M., Youssef, E., Yoo, K., Dorflinger, E., Bausch, A., Alberati, D., & Santarelli, L. (2011) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(11)70841-0

P.1.c.040 Partial occupancy of the glycine transporter type 1 by RG1678 leads to efficacy in animal models relevant to schizophrenia

Alberati, D., Borroni, E., Moreau, J. L., Wong, D., Wallace, T., Hainzl, D., Pinard, E., & Wettstein, J. G. (2011) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(11)70431-x

Electrical synapses and their functional interactions with chemical synapses

Pereda, A. E. (2014) · Nature reviews. Neuroscience · doi:10.1038/nrn3708 · Cited by 855

Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction

Ayalew, M., Le-Niculescu, H., Levey, D. F., Jain, N., Changala, B., Patel, S. D., Winiger, E. A., Breier, A. F., Shekhar, A., AMDUR, R. L., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.37 · Cited by 390

Auditory dysfunction in schizophrenia: integrating clinical and basic features

Javitt, D. C., & Sweet, R. A. (2015) · Nature reviews. Neuroscience · doi:10.1038/nrn4002 · Cited by 377

Has an Angel Shown the Way? Etiological and Therapeutic Implications of the PCP/NMDA Model of Schizophrenia

Javitt, D. C., Zukin, S. R., Heresco-Levy, U., & Umbricht, D. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs069 · Cited by 322

Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis

Hardingham, G. E., & Do, K. Q. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.19 · Cited by 304

Role of Central Glutamatergic Neurotransmission in the Pathogenesis of Psychiatric and Behavioral Disorders

Wang, S., & Yang, T. (2005) · Drug News & Perspectives · doi:10.1358/dnp.2005.18.9.953668 · Cited by 17

Glutamatergic Dysregulation in Depression, Schizophrenia, and Addiction: Mechanisms and Therapeutic Strategies

Shi, W., & Bai, J. (2026) · Actas Españolas de Psiquiatría · doi:10.62641/aep.2307

Glutamatergic Pathways

Smith, Y. (2005) · Humana Press eBooks · doi:10.1007/978-1-59259-852-6_3 · Cited by 1

Translational medicine of the glutamate AMPA receptor

Miyazaki, T., Hiroki, A. B. E., Uchida, H., & Takahashi, T. (2021) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.97.001 · Cited by 12

Glutamate as a therapeutic target in psychiatric disorders

Javitt, D. C. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001551 · Cited by 534